Understanding airway wall remodeling in asthma: A basis for improvements in therapy?

Pharmacology and Therapeutics

Volumn 91, Issue 2, 2001, Pages 93-104

  Kumar, Rakesh K ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Airway inflammation; Airway remodeling; Animal models; Asthma; Cytokines; Growth factors

Indexed keywords

ANTIASTHMATIC AGENT; ANTIINFLAMMATORY AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; CYTOKINE; GROWTH FACTOR; LEUKOTRIENE RECEPTOR BLOCKING AGENT;

AIRWAY; ARTICLE; ASTHMA; CHRONIC DISEASE; DISEASE MODEL; EPITHELIUM CELL; EXPERIMENTAL MODEL; HUMAN; HYPERACTIVITY; INFLAMMATION; INFLAMMATORY CELL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; STROMA CELL;

EID: 0035206065     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(01)00149-8     Document Type: Review

References (150)

1. Detection of cytokines and their cell sources in bronchial biopsy specimens from asthmatic patients: Relationship to atopic status, symptoms, and level of airway hyperresponsiveness
2. Mutual inhibition by TGF-beta and IL-4 in cultured human bronchial epithelial cells
3. Pharmacology of leukotriene receptor antagonists
4. Expression of laminins in the airways in various types of asthmatic patients: A morphometric study
5. Expression of epidermal growth factor and epidermal growth factor receptor immunoreactivity in the asthmatic human airway
6. A new method for bronchial-provocation testing in asthmatic subjects using a dry powder of mannitol
7. Asthma morbidity in Australia: An epidemiological study
8. Cellular events in the bronchi in mild asthma and after bronchial provocation
9. Lung inflammation and epithelial changes in a murine model of atopic asthma
10. Immunological aspects of allergic asthma
11. Interleukin-4 receptor in moderate atopic asthma: A phase I/II randomized, placebo-controlled trial
12. Serum matrix metalloproteinase-9: Tissue inhibitor of metalloproteinase-1 ratio correlates with steroid responsiveness in moderate to severe asthma
13. Airway responsiveness and bronchial-wall thickness in asthma with or without fixed airflow obstruction
14. Eosinophilic inflammation in asthma
15. Asthma: From bronchoconstriction to airways inflammation and remodeling
16. Interleukin-4, -5, and -6 and tumor necrosis factor-α in normal and asthmatic airways: Evidence for the human mast cell as a source of these cytokines
17. Heterogeneity of human mast cells based on cytokine content
18. Eosinophils, T-lymphocytes, mast cells, neutrophils, and macrophages in bronchial biopsy specimens from atopic subjects with asthma: Comparison with biopsy specimens from atopic subjects without asthma and normal control subjects and relationship to bronchial hyperresponsiveness
19. Myofibroblasts and subepithelial fibrosis in bronchial asthma
20. Guidelines for the management of asthma: A summary
21. Evidence of ongoing mast cell and eosinophil degranulation in symptomatic asthma airway
22. Insulin-like growth factor is a major fibroblast mitogen produced by primary cultures of human airway epithelial cells
23. TNFα is important in human lung allergic reactions
24. Bronchial responsiveness to distilled water and methacholine and its relationship to inflammation and remodeling of the airways in asthma
25. Airways remodeling is a distinctive feature of asthma and is related to severity of disease
26. Collagen deposition in large airways may not differentiate severe asthma from milder forms of the disease
27. Tryptase inhibitors block allergen-induced airway and inflammatory responses in allergic sheep
28. Induction of airway mucus production by T helper 2 (Th2) cells: A critical role for interleukin 4 in cell recruitment but not mucus production
29. Human eosinophils can express the cytokines tumor necrosis factor-α and macrophage inflammatory protein-1α
30. Role of cationic proteins in the airway. Hyperresponsiveness due to airway inflammation
31. Dissociation between airway inflammation and airway hyperresponsiveness in allergic asthma
32. The epidermal growth factor receptor and its ligand family: Their potential role in repair and remodelling in asthma
33. Quantitation of mast cells and eosinophils in the bronchial mucosa of symptomatic atopic asthmatics and healthy control subjects using immunohistochemistry
34. Treatment of asthma with drugs modifying the leukotriene pathway
35. The pathology of asthma, with special reference to changes in the bronchial mucosa
36. Airway responsiveness in asthma: Bronchial challenge with histamine and 4.5% sodium chloride before and after budesonide
37. Cellular hypertrophy and hyperplasia of airway smooth muscles underlying bronchial asthma: A 3-D morphometric study
38. Taming TNF: Strategies to restrain this proinflammatory cytokine
39. Airway remodeling in asthma
40. Irreversible airflow obstruction: Evolution in asthma
41. Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model
42. Dissociation of inflammatory and epithelial responses in a murine model of chronic asthma
43. Elevated levels of the eosinophil granule major basic protein in the sputum of patients with bronchial asthma
44. DNA from Mycobacterium bovis Bacillus Calmette-Guerin (MY-1) inhibits immunoglobulin E production by human lymphocytes
45. Chronic cough: Eosinophilic bronchitis without asthma
46. Intraepithelial mast cells in allergic and nonallergic asthma. Assessment using bronchial brushings
47. Increased peak flow variability in children with asymptomatic hyperresponsiveness
48. Increased secretion of tumor necrosis factor α and interleukin-6 by alveolar macrophages consecutive to the development of the late asthmatic reaction
49. Prescribed fenoterol and death from asthma in New Zealand, 1981-7: A further case-control study
50. Requirement for IL-13 independently of IL-4 in experimental asthma
51. Inflammatory cell distribution within and along asthmatic airways
52. The pathology of asthma: An inflammatory disorder
53. The importance of leukotrienes in airway inflammation in a mouse model of asthma
54. Involvement of IL-16 in the induction of airway hyper-responsiveness and up-regulation of IgE in a murine model of allergic asthma
55. Interleukin-5-producing CD4+ T cells play a pivotal role in aeroallergen-induced eosinophilia, bronchial hyperreactivity, and lung damage in mice
56. Dysfunction of pulmonary surfactant in asthmatics after segmental allergen challenge
57. New insights into airway inflammation by endobronchial biopsy
58. Epithelial-mesenchymal interactions in the pathogenesis of asthma
59. Immunoprophylaxis of atopy: Light at the end of the tunnel?
60. Regulation of immune responses at mucosal surfaces: Allergic respiratory disease as a paradigm
61. T-cell "priming" against environmental allergens in human neonates: Sequential deletion of food antigen reactivity during infancy with concomitant expansion of responses to ubiquitous inhalant allergens
62. The role of allergy in the development of asthma
63. Expression of vascular endothelial growth factor by human eosinophils: Upregulation by granulocyte macrophage colony-stimulating factor and interleukin-5
64. Bronchial subepithelial fibrosis and expression of matrix metalloproteinase-9 in asthmatic airway inflammation
65. A clinical and pathological study of fatal cases of status asthmaticus
66. Enhanced proteoglycan deposition in the airway wall of atopic asthmatics
67. Characteristics of bronchial asthma with incomplete reversibility of airflow obstruction
68. Relationship between IL-4 and IL-5 mRNA expression and disease severity in atopic asthma
69. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC
70. Airway smooth muscle in health and disease; methods of measurement and relation to function
71. Testing airway responsiveness using inhaled methacholine or histamine
72. The mechanics of airway narrowing in asthma
73. Antigen-induced airway inflammation in atopic subjects generates dysfunction of pulmonary surfactant
74. Changes in sputum eosinophils predict loss of asthma control
75. Regulation of proliferation of human colonic subepithelial myofibroblasts by mediators important in intestinal inflammation
76. Airway and lung tissue mechanics in asthma: Effects of albuterol
77. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: A randomized, double-blind, placebo-controlled trial
78. Pathology of mild, severe and fatal asthma
79. Late response to allergen is associated with increased concentrations of tumor necrosis factor-α and IL-5 in induced sputum
80. Effect of acute and chronic antigen inhalation on airway morphology and responsiveness in actively sensitized rats
81. A long-term study of the antiinflammatory effect of low-dose budesonide plus formoterol versus high-dose budesonide in asthma
82. Human mast cells and basophils as sources of cytokines
83. Anti-T cell strategies in asthma
84. A murine model of chronic human asthma
85. Airway inflammation in a murine model of chronic asthma: Evidence for a local humoral immune response
86. Inhibition of pulmonary eosinophilia and airway hyperresponsiveness in allergic mice by rolipram: Involvement of endogenously released corticosterone and catecholamines
87. Tenascin is increased in airway basement membrane of asthmatics and decreased by an inhaled steroid
88. Airway mucosal inflammation even in patients with newly diagnosed asthma
89. Bronchial neutrophilia in patients with noninfectious status asthmaticus
90. A 15-year follow-up study of ventilatory function in adults with asthma
91. Interleukin-5 expression in the lung epithelium of transgenic mice leads to pulmonary changes pathognomonic of asthma
92. Tumor necrosis factor-alpha induces mucin hypersecretion and MUC-2 gene expression by human airway epithelial cells
93. Increased vascularity of the bronchial mucosa in mild asthma
94. Interleukin-9 upregulates mucus expression in the airways
95. Effects of an antibody to interleukin-5 in a monkey model of asthma
96. Asthma
97. Asthma
98. Treatment of allergic asthma with monoclonal anti-IgE antibody
99. Eosinophil-associated TGF-β1 mRNA expression and airways fibrosis in bronchial asthma
100. Bronchial biopsy evidence for leukocyte infiltration and upregulation of leukocyte-endothelial cell adhesion molecules 6 hours after local allergen challenge of sensitized asthmatic airways
101. Airway and tissue responses to antigen challenge in sensitized Brown Norway rats
102. Effect of a peptide leukotriene receptor antagonist, ONO-1078, on guinea-pig models of asthma
103. Eotaxin and impaired lung function in asthma
104. Interleukin-8 secretion and neutrophil recruitment accompanies induced sputum eosinophil activation in children with acute asthma
105. Human lung mast cells and pulmonary macrophages produce tumor necrosis factor-α in sensitized lung tissue after IgE receptor triggering
106. Eosinophils as a potential source of platelet-derived growth factor B-chain (PDGF-B) in nasal polyposis and bronchial asthma
107. Transforming growth factor β1 (TGFβ1) gene expression by eosinophils in asthmatic airway inflammation
108. Eosinophils as a source of matrix metalloproteinase-9 in asthmatic airway inflammation
109. Animal models of asthma
110. Prolonged allergen exposure induces structural airway changes in sensitized rats
111. Mitogenic action of tumor necrosis factor in human fibroblasts: Interaction with epidermal growth factor and platelet-derived growth factor
112. Serum IgE levels, atopy, and asthma in young adults: Results from a longitudinal cohort study
113. Exhaled nitric oxide and sputum eosinophil markers of inflammation in asthmatic children
114. Involvement of the epidermal growth factor receptor in epithelial repair in asthma
115. Mast cells are a major source of basic fibroblast growth factor in chronic inflammation and cutaneous hemangioma
116. Proinflammatory potential of the airway epithelium in bronchial asthma
117. Macrophage-derived growth factors
118. Transforming growth factor-β1 in asthma: Measurement in bronchoalveolar lavage fluid
119. Pharmacological evidence for tumor necrosis factor as a mediator of allergic inflammation in the airways
120. Asthma and other atopic diseases in Australian children: Australian arm of the International Study of Asthma and Allergy in Childhood
121. Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma
122. Subepithelial fibrosis in the bronchi of asthmatics
123. Spontaneous production of transforming growth factor-β2 by primary cultures of bronchial epithelial cells
124. Airway wall remodelling after cessation of exposure to isocyanates in sensitized asthmatic subjects
125. Regular inhaled beta-agonist treatment in bronchial asthma
126. Kinetics of the development and recovery of the lung from IgE-mediated inflammation: Dissociation of pulmonary eosinophilia, lung injury, and eosinophil-active cytokines
127. Effect of inhaled interleukin-5 on airway hyperreactivity and eosinophilia in asthmatics
128. Bronchoalveolar lavage in asthma: An update and perspective
129. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment
130. Airway wall remodelling in asthma: A novel target for the development of anti-asthma drugs
131. Ventilatory function in British adults after asthma or wheezing illness at ages 0-35
132. Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid
133. Current outpatient management of asthma shows poor compliance with International Consensus Guidelines
134. An improved murine model of asthma: Selective airway inflammation, epithelial lesions and increased methacholine responsiveness following chronic exposure to aerosolised allergen
135. Tumor necrosis factor-α increases airway responsiveness and sputum neutrophilia in normal human subjects
136. Toward a definition of asthma for epidemiology
137. Autocrine growth loop of the epidermal growth factor receptor in normal and immortalized human bronchial epithelial cells
138. Effects of rolipram on responses to acute and chronic antigen exposure in monkeys
139. Transforming growth factor-β expression in mucosal biopsies in asthma and chronic bronchitis
140. Airway inflammation in mild intermittent and in persistent asthma
141. Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids
142. Eosinophils and mast cells in bronchoalveolar lavage in subjects with mild asthma
143. Integrated signals between IL-13, IL-4, and IL-5 regulate airways hyperreactivity
144. Bronchoscopic evaluation of severe asthma: Persistent inflammation associated with high dose glucocorticoids
145. The measurement of reticular basement membrane and submucosal collagen in the asthmatic airway
146. Shifts in lung lymphocyte profiles correlate with the sequential development of acute allergic and chronic tolerant stages in a murine asthma model
147. Phenotype of cells expressing mRNA for TH2-type (interleukin 4 and interleukin 5) and TH1-type (interleukin 2 interferon γ) cytokines in bronchoalveolar lavage and bronchial biopsies from atopic asthmatic and normal control subjects
148. Growth factors secreted by bronchial epithelial cells control myofibroblast proliferation: An in vitro co-culture model of airway remodeling in asthma
149. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production